Earnings Ahead

CARA - Cara Therapeutics

2.78 0.07 2.58

Cara Therapeutics

Cara Therapeutics

About

Profile

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs).


Headquarters

Stamford, Connecticut, United States


Intraday

High
-
Low
-

52-week

High
-
Low
-

CARA



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Cara Therapeutics GAAP EPS of -$0.52 beats by $0.01, revenue of $4.87M misses by $5.08M
  • Cara Therapeutics Q3 2023 Earnings Preview
  • Cara Therapeutics reports up to $40 million non-dilutive financing agreement
  • Cara Therapeutics GAAP EPS of -$0.58 misses by $0.04, revenue of $6.93M beats by $0.23M
  • Cara Therapeutics Q2 2023 Earnings Preview
  • Jefferies says CMS extension for CARA dialysis drug should "unlock stock"
  • UK drug pricing watchdog backs use of Cara, Vifor's Kapruvia in NHS
  • Cara Therapeutics GAAP EPS of -$0.49 beats by $0.03, revenue of $6.17M beats by $1.19M
  • Cara Therapeutics Q1 2023 Earnings Preview
  • Cara, Iovance, and Karyopharm among biotechs with no exposure to SVB (updated)
  • Cara Therapeutics downgraded at BofA on sales forecast for Korsuva
  • Cara Therapeutics plummets 29% on quarterly misses; enough cash to operate to H1 2024
  • Cara Therapeutics GAAP EPS of -$0.56 misses by $0.20, revenue of $3.26M misses by $11.24M
  • Cara Therapeutics GAAP EPS of -$0.43 beats by $0.01, revenue of $10.81M beats by $1.95M
  • Cara Therapeutics Q3 2022 Earnings Preview
  • SWK Holdings unit receives $5M payment from Cara Therapeutics
  • Cara's partner files for Japanese approval of Korsuva to treat itch in hemodialysis patients
  • Cara Therapeutics hires new finance chief
  • Cara, Vifor's Kapruvia gets approval in Switzerland to treat itch in hemodialysis patients
  • Cara Therapeutics GAAP EPS of -$0.08 beats by $0.18, revenue of $23M beats by $1.97M

Earnings History

Date EPS / Forecast Revenue / Forecast
November 8, 2021 -0.02 / -0.3863 20.27M / 15.59M Beat!
August 9, 2021 -0.61 / -0.5483 - / -
May 10, 2021 -0.47 / -0.5733 1.94M / 3.03M
February 25, 2021 1.59 / 0.3643 112.09M / 5.98M Beat!
November 9, 2020 -0.35 / -0.5971 9.27M / 4.73M Beat!
August 10, 2020 -0.54 / -0.67 5.63M / 5.01M Beat!
May 11, 2020 -0.62 / -0.6 8.09M / 4.71M Beat!
February 27, 2020 -0.61 / -0.66 4.51M / 5.39M
November 5, 2019 -0.74 / -0.58 5.79M / 4.84M Beat!
August 7, 2019 -0.58 / -0.61 5.21M / 3.06M Beat!
May 7, 2019 -0.56 / -0.58 4.38M / 3.29M Beat!
March 12, 2019 -0.52 / -0.58 5.53M / 2.67M Beat!
November 6, 2018 -0.51 / -0.49 5.06M / 3.4M Beat!
August 7, 2018 -0.52 / -0.51 2.87M / 150K
May 9, 2018 -0.51 / -0.47 188K / 62.67K Beat!
March 15, 2018 -0.43 / -0.40 2.87M / 0.02M Beat!
November 2, 2017 -0.38 / -0.34 2.87M / 0.19M Beat!
August 3, 2017 -0.29 / -0.62 2.87M / 0.02M Beat!
May 4, 2017 -0.81 / -0.62 911.0K / - Beat!
Date Price Open High Low Vol Change
Jan 29 4.99 4.86
5.27
4.81
32.7K 2.67%
Jan 28 4.86 5.37
5.4
4.86
21.0K -10.17%
Jan 27 5.41 5.99
6
5.11
44.7K -9.68%
Jan 24 5.99 5.17
5.99
5.02
112K 18.38%
Jan 23 5.06 4.74
5.11
4.66
49.2K 5.86%
 
Jan 22 4.78 4.61
4.81
4.6
33.0K 3.91%
Jan 21 4.6 4.64
4.82
4.56
57.2K -1.08%
Jan 17 4.65 4.68
4.79
4.51
11.3K 1.09%
Jan 16 4.6 4.33
4.8
4.32
47.7K 3.14%
Jan 15 4.46 4.75
4.8
4.46
45.3K -4.5%
Jan 14 4.67 4.67
4.85
4.3
60.8K 0.21%
Jan 13 4.66 4.71
4.92
4.51
180K -1.89%
Jan 10 4.75 4.54
4.83
4.44
135K 0%
Jan 8 4.75 4.73
4.92
4.54
45.5K -2.66%
Jan 7 4.88 5.22
5.22
4.75
89.5K -5.61%
Jan 6 5.17 5.1
5.52
5.05
58.8K -0.96%
Jan 3 5.22 5.24
5.39
4.73
92.5K -2.61%
Jan 2 5.36 5.81
5.81
5.1
128K -12.42%
Dec 31, 2024 6.12 4.18
6.36
4.15
334K 43.66%
Dec 30, 2024 4.26 4.44
4.68
3.96
187K -6.17%
Dec 27, 2024 4.54 5.4
5.49
4.32
245K -15.93%
Dec 26, 2024 5.4 5.46
5.52
4.69
69.0K -2.88%
Dec 24, 2024 5.56 5.49
5.67
4.93
101K 1.28%
Dec 23, 2024 5.49 5.11
5.73
4.8
188K 8.28%
Dec 20, 2024 5.07 4.13
5.52
4.08
446K 3.26%
Dec 19, 2024 4.91 3.11
6.23
3.04
2.2M 55.87%
Dec 18, 2024 3.15 2.9
3.26
2.71
1.9M 5%
Dec 17, 2024 3 3.06
3.07
2.87
115K -3.23%
Dec 16, 2024 3.1 3.05
3.25
3
50.9K -1.27%
Dec 13, 2024 3.14 3.32
3.32
2.9
84.4K 0%
Dec 12, 2024 3.14 3.13
3.34
3.12
29.6K -1.88%
Dec 11, 2024 3.2 3.26
3.38
3.18
30.6K -2.14%
Dec 10, 2024 3.27 3.49
3.5
3.24
26.2K -6.57%
Dec 9, 2024 3.5 3.1
3.6
3.1
84.4K 9.72%
Dec 6, 2024 3.19 3.36
3.36
3.06
47.5K -1.24%
Dec 5, 2024 3.23 3.24
3.32
3.12
17.4K -1.82%
Dec 4, 2024 3.29 3.47
3.47
3.16
51.9K -1.2%
Dec 3, 2024 3.33 3.42
3.49
3.33
37.8K -4.58%
Dec 2, 2024 3.49 3.6
3.72
3.42
47.9K -4.38%
Nov 29, 2024 3.65 3.43
3.67
3.43
9.0K 5.49%
Nov 27, 2024 3.46 3.42
3.58
3.42
27.0K -0.57%
Nov 26, 2024 3.48 3.66
3.66
3.42
54.6K -4.92%
Nov 25, 2024 3.66 3.65
3.82
3.54
45.6K 0%
Nov 22, 2024 3.66 3.7
3.79
3.4
42.4K -1.61%
Nov 21, 2024 3.72 3.62
3.78
3.6
14.5K 1.64%
Nov 20, 2024 3.66 3.61
3.78
3.6
17.1K 1.39%
Nov 19, 2024 3.61 3.48
3.88
3.34
93.8K 2.85%
Nov 18, 2024 3.51 3.73
3.83
3.48
66.5K -5.9%
Nov 15, 2024 3.73 3.84
3.96
3.54
46.2K -5.09%
Nov 14, 2024 3.93 3.84
4.01
3.78
33.9K 1.03%
Nov 13, 2024 3.89 3.97
4.14
3.89
53.5K -4.89%
Nov 12, 2024 4.09 4.11
4.2
3.9
60.7K 0%
Nov 11, 2024 4.09 4.02
4.2
3.83
92.3K 0.25%
Nov 8, 2024 4.08 4.22
4.42
3.9
128K -1.45%
Nov 7, 2024 4.14 3.84
4.28
3.74
241K 10.70%
Nov 6, 2024 3.74 3.54
3.96
3.41
121K 7.16%
Nov 5, 2024 3.49 3.48
3.66
3.37
24.3K -0.29%
Nov 4, 2024 3.5 3.48
3.6
3.39
24.1K -1.69%
Nov 1, 2024 3.56 3.72
3.77
3.49
23.5K -4.3%
Oct 31, 2024 3.72 3.49
3.84
3.39
154K 0%